Our results reveal that, despite a large number of polymorphisms located in the promoter region, the exonic variants are those expected to have a potential in vivo effect.
INTRODUCTION
UDP-glucuronosyltransferase (UGT) enzymes comprise a superfamily of membrane proteins that catalyze the glucuronidation of a wide range of xenobiotics and endogenous compounds. As a major pathway the among phase II reactions in drug metabolism, interindividual variation in the glucuronidation pathway has received much attention and a number of genetic variations has been described, some of which have a clear pharmacological impact. To this day, nineteen functional proteins have been described, classified into three subfamilies: UGT1A, UGT2A and UGT2B [1] [2] [3] . The subfamily UGT1 includes nine active UGT isoforms encoded by a single gene UGT1 than spans 200kb. The UGT1A isoforms are encoded by four shared exons (2-5) that code for the carboxy terminal region of the protein, and variable exons 1, which corresponds to the substrate binding domain and provides differential substrate specificity [4] . UGT1A4, together with UGT1A3, is the main enzyme responsible for addition of glucuronic acid to amino groups (N-glucuronidation) [5, 6] . The UGT1A4 protein is primarily expressed in the liver and in bile ducts, colon and small intestine. This enzyme exhibits catalytic activities mostly for primary and secondary amines, present in various therapeutic drugs [7] . Among these are a number of psychiatric drugs, including tricyclic antidepressants, antipsychotics and anticonvulsants. Trifluoperazine (TFP) is known to be readily and specifically glucuronidated by UGT1A4 [8] . The UGT1A4 enzyme was also reported to have the capacity to generate one of the glucuronides of the dietary carcinogen N-OH-PhIP found in cooked meat [9, 10] . Tamoxifen, a nonsteroidal 4 4 antiestrogen widely used for chemotherapy of hormone-dependent breast cancer, was also reported as a substrate for this enzyme [11] . Genetic variability in tamoxifen metabolism is one putative causal factor associated with interpatient variability in response to therapy [12] . Tamoxifen can be converted into several oxidative compounds [13] , including 4-OH-tamoxifen, which is considered as its active metabolite, and both are shown to be metabolized by UGT1A4 into ammonium-linked glucuronides [11, 12, 14] .
Frequency of genetic variations and haplotypes in UGT1A4 has been described for the Caucasian and Japanese populations, however, these studies included limited analysis of the promoter and intronic regions [15] [16] [17] . A careful evaluation of the function of UGT1A4 coding region polymorphisms has been limited to the P 24 T and L 48 V variants [15, 18] . In contrast, only two promoter variations (-163G>A and -219C>T) were evaluated in vitro in a single study [19] .
The main objective of this study was 1) to screen the UGT1A4 gene for polymorphisms in the promoter and coding region, from -4962bp relative to the transcription start site to 2000bp after the first exon, and, 2) to establish their potential effect on UGT1A4 enzymatic function and expression in vitro.
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METHODS
Materials
Methanol, acetonitrile and formic acid were purchased from VWR (Montreal, Canada). Ammonium formate was purchased from Laboratoire Mat (Quebec, Canada).
Tamoxifen, z-4-hydroxytamoxifen, -glucuronidase type VII from E. Coli and UDPglucuronic acid were obtained from Sigma-Aldrich (St. Louis, MO). N-hydroxy-2-amino-1-methyl-6-phenylimidazo [4,5-b] DNA samples from 100 unrelated Caucasians and from 36 Caucasian/AfricanAmerican were described from previous studies [20, 21] . Liver microsomes, DNA and RNA from American subjects were used as described previously [22, 23] . All subjects provided written consent for experimental purposes, and the Institutional Review Boards approved the use of these samples. Table 1 . PCR conditions were 95°C for 1 min for initial denaturation, followed by 40 cycles at 95°C for 30 sec, 55-65°C for 30-40 sec and 72°C for 1-1.5 min, with a final extension at 72°C for 7 min. Specificity of primers was confirmed by direct sequencing of all PCR products. Amplicons were sequenced with an ABI 3700 automated sequencer using Big Dye (PerkinElmer Life Sciences, Boston, MA) dye primer chemistry. Samples were sequenced on both strands with primers listed in 
UGT1A4 sequencing
UGT1A4 variants and microsomal preparations
UGT1A4 variant alleles were generated by site-directed mutagenesis using the pcDNA3 vector, using a procedure described previously [24, 25] . Stable HEK293 cell transfection with variant pcDNA3-UGT expression plasmids, preparation of microsomes 7 7 by differential centrifugation, and assessment of UGT protein levels by Western blot have been previously described [24] [25] [26] .
Transient transfections of UGT1A4 promoter constructs
Reference and variant promoter constructs of 606 bp were isolated by PCR from carriers of reference ( The procedure for enzymatic assays with N-OH-PhIP and trifluoperazine was described previously [8, 28] . Statistical evaluation of best-fit model was used to select the enzyme 
LC/MS analysis of glucuronide products
Detection of UGT1A4-generated N-OH-PhIP and TFP glucuronides was performed as described previously [8, 10] . For the detection of tamoxifen, 4-hydroxytamoxifen glucuronides, the LC-MS/MS system consisted of a mass spectrometer (model API 3200, Concord, Canada) operated in multiple reactions monitoring mode acetonitrile 0,1% acid formic (v/v). Separation was achieved using a linear gradient of 45-60% B in 2.0min at a flow rate of 0.9 ml/min. Then, the column was flushed with 95%B
for 2 minutes and re-equilibrated to initial conditions over 3 min. For the Z-OHtamoxifen glucuronide, the chromatographic separation was achieved with a ACE-3 HL column with 3 m packing material, 100 X 4.6 mm (Life Science, Peterborough, Canada). The mobiles phases were (solvent A) water 0,4% formic acid (v/v) and (solvent B) methanol. Separation was achieved using isocratic conditions of 30% A and 70% B for 3 minutes at a flow rate of 0.9 ml/min. The column was flushed with 95%B for 2 minutes and re-equilibrated to initial conditions over 3 min.
UGT1A4 Quantitative Real-time-PCR
UGT1A4 RNA was quantified in the liver samples and expression levels were normalized for r18S content [29] . Briefly, reverse transcription reaction was performed 
Statistical analyses
All statistical analyses were performed with the JMP software v4.0. Leu) (Fig. 1A) . In the 100 Caucasian individuals, 13 intronic and 39 promoter polymorphisms were found. Linkage disequilibrium (LD) analyses revealed a strong linkage between most promoter SNPs and also between intronic SNPs, resulting in two block structures, which were also in relatively elevated linkage (67%) (Fig. 2 ).
Haplotypes were inferred in the cohort of Caucasian individuals (n=100) and revealed the existence nine different haplotypes of variable frequencies (Fig. 3) . A series of variations in the promoter region (haplotypes *3a, *3c and *3d) were found to be in complete LD with the previously reported L 48 V coding region variant, with an allelic frequency of 6%.
These variations were also frequently associated with a series of intronic variations (haplotypes *3c and *3d).
Computational analysis of UGT1A4 promoter variations
To better assess if these variants could potentially modulate the transcription of However, no significant differences were observed in luciferase activity between the reference and variant promoter (-163A, -219T, -419A, -457T) constructs with the addition of either or both the HNF-1 and OCT-1 transcription factors in two of the three cell lines (Fig. 5) . These results suggest that those promoter variants, using a proximal 13 13 construction around 500 bp of the UGT1A4 promoter, do not substantially modify gene expression.
UGT1A4 coding variants modulate in vitro glucuronide formation
Several UGT1A4 coding variants have been previously shown to alter in vitro glucuronidation. To confirm and extend upon these observations, we performed enzymatic assays and included the less frequent coding variations. For these assays, tamoxifen and Z-4-hydroxytamoxifen were tested ( , respectively, also resulted in markedly reduced the V max /K m for these two substrates.
Correlation between the presence of genetic variations, UGT1A4 mRNA, and glucuronidation activity in a human liver bank
In order to study the potential influence of identified UGT1A4 variants, UGT1A4
RNA expression and formation of TFP-glucuronide, as well as glucuronide 1 of N-OHPhIP (uncharacterized at this time), were correlated with UGT1A4 genotypes (-2497A>G, 
DISCUSSION
UGT1A4 is the one of the major enzymes responsible for the N-glucuronidation of various compounds, including therapeutic drugs [5] [6] [7] . In previous studies, UGT1A4
was demonstrated to have the capacity to conjugate antihistamines (cyproheptadine), tricyclic antidepressants (imipramine) and of numerous antipsychotics (clozapine, trifluoperazine) [10, 15, 30] . UGT1A4 was also found to generate tamoxifen and 4-OHtamoxifen glucuronides [11] , as well as one of the glucuronides of N-OH-PhIP, a dietary carcinogen found in cooked meat [9, 10] . For a number of these compounds, metabolic variations were predicted to originate from individual genetic profiles of UGT enzymes.
While a number of coding region polymorphisms, including the P
24
T and L
48
V variants, have been described, the 5'-untranslated region of the UGT1A4 gene has not been as extensively studied [18, 31] . Although UGT1A4 variations have previously been described in the Caucasian and Japanese population [15] [16] [17] , to our knowledge, the present study is the most extensive to have been published so far. UGT1A and 2B genes, including UGT1A4 [32] . In turn, OCT-1 was previously reported to bind to HNF-1, consequently enhancing its capacity to activate the UGT2B7 promoter [33] . The increased activity observed in the hepatic cell line HepG2 upon co-transfection with these transcription factors confirms their likely role in UGT1A4 regulation. In a previous study, the -163T variation was found to be associated with significantly reduced transcriptional activity upon transient transfection [19] . Although a similar observation was done in our study, the complete haplotype (-163T, -219A, 419T and -463A) did not show such a repression, despite its possible association with the addition and deletion of HNF-1 and OCT-1 putative binding sites. Since several other SNPs have also been found in the region beyond -1000 bp, additional studies will be required to carefully assess the contribution of the distal promoter in the transcriptional regulation of the UGT1A4 gene and the potential influence of variable amino acids.
Several coding variants in the
Kinetic analysis with tamoxifen and 4-hydroxytamoxifen have been previously published [11, 14] , while only the effect of variants P
24
T and L 48 V had been assessed for these substrates. The apparent K m derived in this study were in a range similar to those observed by Kaku et al. [11] , but higher than those noted by Sun et al. [14] . , all of which are likely to be functionally significant since they are associated with reduced UGT1A4 activity with one or both substrates.
Despite the fact that several variants are predicted to modulate glucuronidation Variants at codons 24 and 48 were already reported. Marie-Odile Benoit-Biancamano 
